曲伐沙星（CP 99,219）与其他抗菌药物对临床重要厌氧菌的体外活性比较
Comparative in vitro activities of trovafloxacin (CP 99,219) and other antimicrobials against clinically significant anaerobes.
作者信息
Aldridge K E, Ashcraft D, Bowman K A
机构信息
Department of Medicine, Louisiana State University Medical Center, New Orleans 70112, USA.
出版信息
Antimicrob Agents Chemother. 1997 Feb;41(2):484-7. doi: 10.1128/AAC.41.2.484.
Abstract
A total of 590 strains of clinically important anaerobes were tested to determine their susceptibility to trovafloxacin. Overall, trovafloxacin had a mode MIC of 0.25 micrograms/ml and a MIC at which 90% of the isolates were inhibited of 1 micrograms/ml and had activity comparable to that of metronidazole. Trovafloxacin was 8-, 8-, 16-, 32-, and 64-fold more active than ampicillin-sulbactam, clindamycin, ciprofloxacin, cefoxitin, and cefotetan, respectively. Of the Bacteroides fragilis group, 97% of the isolates were inhibited by trovafloxacin at 21 micrograms/ml, and trovafloxacin was more active than ciprofloxacin, cefoxitin, cefotetan, ampicillin-sulbactam, and clindamycin against Clostridium, Fusobacterium, Porphyromonas, and Prevotella strains.
摘要
共检测了590株具有临床重要性的厌氧菌，以确定它们对曲伐沙星的敏感性。总体而言，曲伐沙星的MIC模式值为0.25微克/毫升，90%的分离株被抑制时的MIC为1微克/毫升，其活性与甲硝唑相当。曲伐沙星分别比氨苄西林-舒巴坦、克林霉素、环丙沙星、头孢西丁和头孢替坦活跃8倍、8倍、16倍、32倍和64倍。在脆弱拟杆菌组中，97%的分离株在2微克/毫升时被曲伐沙星抑制，并且曲伐沙星对梭菌属、梭杆菌属、卟啉单胞菌属和普雷沃菌属菌株的活性高于环丙沙星、头孢西丁、头孢替坦、氨苄西林-舒巴坦和克林霉素。
相似文献
1
Comparative in vitro activities of trovafloxacin (CP 99,219) and other antimicrobials against clinically significant anaerobes.
Antimicrob Agents Chemother. 1997 Feb;41(2):484-7. doi: 10.1128/AAC.41.2.484.
2
Comparison of activities of trovafloxacin (CP-99,219) and five other agents against 585 anaerobes with use of three media.
Clin Infect Dis. 1996 Dec;23 Suppl 1:S44-50. doi: 10.1093/clinids/23.supplement_1.s44.
3
In vitro activity of gemifloxacin (SB 265805) against anaerobes.
Antimicrob Agents Chemother. 1999 Sep;43(9):2231-5. doi: 10.1128/AAC.43.9.2231.
4
In vitro activities of trovafloxacin against 557 strains of anaerobic bacteria.
Antimicrob Agents Chemother. 1996 Sep;40(9):2232-5. doi: 10.1128/AAC.40.9.2232.
5
Synergic activity, for anaerobes, of trovafloxacin with clindamycin or metronidazole: chequerboard and time-kill methods.
J Antimicrob Chemother. 2000 May;45(5):633-8. doi: 10.1093/jac/45.5.633.
6
Activities of gatifloxacin compared to those of seven other agents against anaerobic organisms.
Antimicrob Agents Chemother. 1998 Sep;42(9):2459-62. doi: 10.1128/AAC.42.9.2459.
7
Susceptibilities of 428 gram-positive and -negative anaerobic bacteria to Bay y3118 compared with their susceptibilities to ciprofloxacin, clindamycin, metronidazole, piperacillin, piperacillin-tazobactam, and cefoxitin.
Antimicrob Agents Chemother. 1993 Aug;37(8):1649-54. doi: 10.1128/AAC.37.8.1649.
8
The in-vitro activity of trovafloxacin and nine other antimicrobials against 413 anaerobic bacteria.
J Antimicrob Chemother. 1996 Aug;38(2):271-81. doi: 10.1093/jac/38.2.271.
9
Activity of CP 99,219 compared with those of ciprofloxacin, grepafloxacin, metronidazole, cefoxitin, piperacillin, and piperacillin-tazobactam against 489 anaerobes.
Antimicrob Agents Chemother. 1994 Oct;38(10):2471-6. doi: 10.1128/AAC.38.10.2471.
10
Time-kill study of the activity of trovafloxacin compared with ciprofloxacin, sparfloxacin, metronidazole, cefoxitin, piperacillin and piperacillin/tazobactam against six anaerobes.
J Antimicrob Chemother. 1997 Jun;39 Suppl B:23-7. doi: 10.1093/jac/39.suppl_2.23.
引用本文的文献
1
The new fluoroquinolones: A critical review.
Can J Infect Dis. 1999 May;10(3):207-38. doi: 10.1155/1999/378394.
2
[Ampicillin and sulbactam concentrations in the irradiated mandible after oral squamous cell cancer].
Mund Kiefer Gesichtschir. 2005 Jul;9(4):214-9. doi: 10.1007/s10006-005-0615-7.
3
Antibiotic resistance in bacteria isolated from subgingival plaque in a norwegian population with refractory marginal periodontitis.
Antimicrob Agents Chemother. 2003 Apr;47(4):1443-6. doi: 10.1128/AAC.47.4.1443-1446.2003.
4
In vivo efficacy of trovafloxacin against Bacteroides fragilis in mixed infection with either Escherichia coli or a vancomycin-resistant strain of Enterococcus faecium in an established-abscess murine model.
Antimicrob Agents Chemother. 2001 May;45(5):1394-401. doi: 10.1128/AAC.45.5.1394-1401.2001.
5
In vitro activity of trovafloxacin against Bacteroides fragilis in mixed culture with either Escherichia coli or a vancomycin- resistant strain of Enterococcus faecium determined by an anaerobic time-kill technique.
Antimicrob Agents Chemother. 2001 Jan;45(1):243-51. doi: 10.1128/AAC.45.1.243-251.2001.
6
Accumulation of norfloxacin by Bacteroides fragilis.
Antimicrob Agents Chemother. 2000 Sep;44(9):2361-6. doi: 10.1128/AAC.44.9.2361-2366.2000.
7
Comparative in vitro activities of clinafloxacin and trovafloxacin against 1,000 isolates of bacteroides fragilis group: effect of the medium on test results.
Antimicrob Agents Chemother. 2000 Jun;44(6):1710-2. doi: 10.1128/AAC.44.6.1710-1712.2000.
8
The future of the quinolones.
Drugs. 1999;58 Suppl 2:1-5. doi: 10.2165/00003495-199958002-00001.
9
In vitro activities of gatifloxacin, two other quinolones, and five nonquinolone antimicrobials against obligately anaerobic bacteria.
Antimicrob Agents Chemother. 1999 Nov;43(11):2783-6. doi: 10.1128/AAC.43.11.2783.
10
Beta-lactamase production in Prevotella intermedia, Prevotella nigrescens, and Prevotella pallens genotypes and in vitro susceptibilities to selected antimicrobial agents.
Antimicrob Agents Chemother. 1999 Oct;43(10):2383-8. doi: 10.1128/AAC.43.10.2383.
本文引用的文献
1
In vivo efficacy of trovafloxacin (CP-99,219), a new quinolone with extended activities against gram-positive pathogens, Streptococcus pneumoniae, and Bacteroides fragilis.
Antimicrob Agents Chemother. 1995 Oct;39(10):2210-6. doi: 10.1128/AAC.39.10.2210.
2
Pharmacokinetics and safety of trovafloxacin (CP-99,219), a new quinolone antibiotic, following administration of single oral doses to healthy male volunteers.
J Antimicrob Chemother. 1995 Aug;36(2):385-94. doi: 10.1093/jac/36.2.385.
3
In vitro activity of CP-99,219, a new fluoroquinolone, against clinical isolates of gram-positive bacteria.
Antimicrob Agents Chemother. 1993 Feb;37(2):366-70. doi: 10.1128/AAC.37.2.366.
4
Patterns of susceptibility to fluoroquinolones among anaerobic bacterial isolates in the United States.
Clin Infect Dis. 1993 Jun;16 Suppl 4:S377-81. doi: 10.1093/clinids/16.supplement_4.s377.
5
In vitro antimicrobial activity of CP-99,219, a novel azabicyclo-naphthyridone.
Antimicrob Agents Chemother. 1993 Feb;37(2):349-53. doi: 10.1128/AAC.37.2.349.
6
Increased activity of a new chlorofluoroquinolone, BAY y 3118, compared with activities of ciprofloxacin, sparfloxacin, and other antimicrobial agents against anaerobic bacteria.
Antimicrob Agents Chemother. 1994 Jul;38(7):1671-4. doi: 10.1128/AAC.38.7.1671.
7
Activity of CP 99,219 compared with those of ciprofloxacin, grepafloxacin, metronidazole, cefoxitin, piperacillin, and piperacillin-tazobactam against 489 anaerobes.
Antimicrob Agents Chemother. 1994 Oct;38(10):2471-6. doi: 10.1128/AAC.38.10.2471.
8
The in-vitro activity of CP 99,219, a new naphthyridone antimicrobial agent: a comparison with fluoroquinolone agents.
J Antimicrob Chemother. 1995 Jun;35(6):869-76. doi: 10.1093/jac/35.6.869.
9
Effect of inoculum, pH, and medium on the activity of ciprofloxacin against anaerobic bacteria.
Antimicrob Agents Chemother. 1984 Mar;25(3):342-3. doi: 10.1128/AAC.25.3.342.
10
The fluoroquinolones: structures, mechanisms of action and resistance, and spectra of activity in vitro.
Antimicrob Agents Chemother. 1985 Oct;28(4):581-6. doi: 10.1128/AAC.28.4.581.
Zotero 插件